Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.45 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.45 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.45 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.33 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29941209 | 1.00 | CSNK2A2 (0.45) | CSNK2A2CSNK2BCSNK2A1ADORA2AADORA1 | |
| SCHEMBL15825576 | 0.68 | AMY1A (0.33) | — | |
| SCHEMBL7044508 | 0.67 | CYP1A2 (0.38) | CSNK2A2CSNK2BCSNK2A1ADORA2AADORA1 | |
| SCHEMBL1759417 | 0.65 | CSNK2A2 (0.45) | CSNK2A2CSNK2BCSNK2A1 | |
| SCHEMBL248855 | 0.65 | NOS1 (0.44) | CSNK2A2CSNK2BCSNK2A1ADORA2AADORA1 | |
| SCHEMBL9306670 | 0.63 | GRIN2D (0.33) | CSNK2A2CSNK2BCSNK2A1ADORA2AADORA1 | |
| SCHEMBL17731632 | 0.63 | HPGD (0.49) | — | |
| SCHEMBL16809167 | 0.58 | CSNK2A1 (0.39) | CSNK2A1ADORA2AADORA1 | |
| SCHEMBL356679 | 0.57 | TDP1 (0.56) | CSNK2A2CSNK2BCSNK2A1 | |
| SCHEMBL441602 | 0.56 | GAA (0.53) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200206188-A1 | COMPOSITIONS AND METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF INDIRUBIN AND ANALOGS THEREOF, INCLUDING MEISOINDIGO | BROWN DENNIS M (US) | 2020-07-02 | — | — | US | claimed |
| US-20160243077-A1 | COMPOSITIONS AND METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF INDIRUBIN AND ANALOGS THEREOF, INCLUDING MEISOINDIGO | BROWN DENNIS M (US) | 2016-08-25 | — | — | US | claimed |
| US-20230057309-A1 | Inhibitors of DREAM Complex Assembly and/or Function For Use In Repairing DNA Damage | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. | 2023-02-23 | — | — | US | disclosed |
| EP-4091611-A1 | INHIBITORS OF DREAM COMPLEX ASSEMBLY AND/OR FUNCTION FOR USE IN REPAIRING DNA DAMAGE | Schumacher, Björn (DE) | 2022-11-23 | — | — | EP | disclosed |
| EP-4091610-A1 | INHIBITORS OF DREAM COMPLEX ASSEMBLY AND/OR FUNCTION FOR USE IN REPAIRING DNA DAMAGE | Schumacher, Björn (DE) | 2022-11-23 | — | — | EP | disclosed |
| EP-3458047-B1 | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR TREATING MICROBIOME DYSREGULATIONS ASSOCIATED WITH CIRCADIAN CLOCK DISRUPTION | INST NAT SANTE RECH MED (FR) | 2022-08-03 | — | — | EP | disclosed |
| US-11364219-B2 | Methods and pharmaceutical compositions for treating microbiome dysregulations associated with circadian clock disruption | INSERM (INSTITUT NATION DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE) (FR) | 2022-06-21 | — | — | US | disclosed |
| US-20200206188-A1 | COMPOSITIONS AND METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF INDIRUBIN AND ANALOGS THEREOF, INCLUDING MEISOINDIGO | BROWN DENNIS M (US) | 2020-07-02 | — | — | US | disclosed |
| US-10383847-B2 | Compositions and methods to improve the therapeutic benefit of indirubin and analogs thereof, including meisoindigo | BROWN DENNIS M (US) | 2019-08-20 | — | — | US | disclosed |
| EP-2585059-B1 | USE OF DIBENZOFURANONE DERIVATIVES TO INHIBIT KINASES | JOSE JOACHIM (DE) | 2017-08-09 | — | — | EP | disclosed |
| US-20160243077-A1 | COMPOSITIONS AND METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF INDIRUBIN AND ANALOGS THEREOF, INCLUDING MEISOINDIGO | BROWN DENNIS M (US) | 2016-08-25 | — | — | US | disclosed |
| WO-2010096751-A1 | COMPOSITIONS AND METHODS FOR TREATING A DISEASE MEDIATED BY SOLUBLE OLIGOMERIC AMYLOID BETA | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2010-08-26 | — | — | WO | disclosed |
| US-20100048657-A1 | CONTROL OF MALIGNANT CELLS PROLIFERATION THROUGH THE INHIBITION OF CASEIN KINASE 2 | CLEVELAND STATE UNIVERSITY (US) | 2010-02-25 | — | — | US | disclosed |
| US-20090239921-A1 | METHODS FOR TREATING NEOPLASMS WITH DERIVATIVES OF 4,5,6,7-TETRABROMOBENZIMIDAZOLE | SELVITA SP. Z.O.O. (PL) | 2009-09-24 | — | — | US | disclosed |
| US-7528259-B2 | Derivatives of 4,5,6,7-tetrabromobenzimidazole and method of their preparation | SELVITA SP. Z O. O. (PL) | 2009-05-05 | — | — | US | disclosed |
| WO-2008033308-A2 | CONTROL OF MALIGNANT CELLS PROLIFERATION THROUGH THE INHIBITION OF CASEIN KINASE 2 | CLEVELAND STATE UNIVERSITY (US) | 2008-03-20 | — | — | WO | disclosed |
| US-20070213385-A1 | NEW DERIVATIVES OF 4,5,6,7-TETRABROMOBENZIMIDAZOLE AND METHOD OF THEIR PREPARATION | SELVITA S.A. (PL) | 2007-09-13 | — | — | US | disclosed |
| EP-1778647-A1 | NEW DERIVATIVES OF 4, 5, 6, 7-TETRABROMOBENZIMIDAZOLE AND METHOD OF THEIR PREPARATION | FUNDACJA ROZWOJU DIAGNOSTYKI I TERATII (PL) | 2007-05-02 | — | — | EP | disclosed |
| WO-2005092866-A1 | NEW DERIVATIVES OF 4, 5, 6, 7-TETRABROMOBENZIMIDAZOLE AND METHOD OF THEIR PREPARATION | FUNDACJA ROZWOJU DIAGNOSTYKI I TERATII (PL) | 2005-10-06 | — | — | WO | disclosed |
| WO-2001083457-A2 | BENZIMIDAZOLE-2-CARBAMATES AND THEIR USE IN CANCER TREATMENT | THE PROCTER & GAMBLE COMPANY (US) | 2001-11-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10383847-B2 | Compositions and methods to improve the therapeutic benefit of indirubin and analogs thereof, including meisoindigo | NEK9, NEK7, NEK3 | CSNK2A2 161/4885CSNK2B 190/4885CSNK2A1 132/4885 |
| US-20100048657-A1 | CONTROL OF MALIGNANT CELLS PROLIFERATION THROUGH THE INHIBITION OF CASEIN KINASE 2 | CSNK2A2, CSNK2A1, CSNK1G2 | CSNK2A2 1/4885CSNK2B 7/4885CSNK2A1 2/4885 |
| US-20200206188-A1 | COMPOSITIONS AND METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF INDIRUBIN AND ANALOGS THEREOF, INCLUDING MEISOINDIGO | NEK9, NEK7, NEK3 | CSNK2A2 161/4885CSNK2B 190/4885CSNK2A1 132/4885 |
| US-11364219-B2 | Methods and pharmaceutical compositions for treating microbiome dysregulations associated with circadian clock disruption | PER2, CRY1, CRY2 | CSNK2A2 4/4885CSNK2B 7/4885CSNK2A1 5/4885 |
| US-20070213385-A1 | NEW DERIVATIVES OF 4,5,6,7-TETRABROMOBENZIMIDAZOLE AND METHOD OF THEIR PREPARATION | CYP3A4, IL4I1, CYP4B1 | CSNK2A2 1023/4885CSNK2B 840/4885CSNK2A1 1059/4885 |
| US-20090239921-A1 | METHODS FOR TREATING NEOPLASMS WITH DERIVATIVES OF 4,5,6,7-TETRABROMOBENZIMIDAZOLE | CSNK2A2, CSNK2A1, CSNK2B | CSNK2A2 1/4885CSNK2B 3/4885CSNK2A1 2/4885 |
| US-20160243077-A1 | COMPOSITIONS AND METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF INDIRUBIN AND ANALOGS THEREOF, INCLUDING MEISOINDIGO | NEK9, NEK7, NEK3 | CSNK2A2 161/4885CSNK2B 190/4885CSNK2A1 132/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.